Welcome to our dedicated page for Seres Therapeutics news (Ticker: MCRB), a resource for investors and traders seeking the latest updates and insights on Seres Therapeutics stock.
Seres Therapeutics Inc (Nasdaq: MCRB) is a clinical-stage biotechnology leader developing microbiome therapies to treat dysbiosis-related conditions. This page provides investors and medical professionals with essential updates on FDA milestones, clinical trial progress, and strategic collaborations shaping the future of ecobiotic treatments.
Access authoritative reports on regulatory approvals, research breakthroughs, and financial developments in one centralized hub. Our curated news collection includes updates on VOWST commercialization, pipeline candidates like SER-155, and partnerships advancing microbiome science.
Key coverage areas include clinical trial results, manufacturing innovations, and peer-reviewed research insights. All content is verified through primary sources to ensure accuracy for investment analysis and medical decision-making.
Bookmark this page for real-time updates on Seres Therapeutics' progress in redefining microbiome-based healthcare solutions. Check back regularly for objective reporting on developments impacting both patient care and long-term corporate strategy.
Seres Therapeutics (MCRB) reported a net loss of $35.5 million in Q1 2021, an increase from $19.9 million in Q1 2020. The rise in losses stemmed from increased clinical and development expenses, totaling $29.3 million in R&D for the quarter. Despite financial losses, the company continues to progress in its clinical pipeline, with the SER-287 Phase 2b study fully enrolled and results expected mid-2021, while SER-109 shows promising outcomes from its Phase 3 study. Seres ended the quarter with $272.5 million in cash and investments.
Seres Therapeutics, Inc. (Nasdaq: MCRB) will host a conference call on May 4, 2021, at 8:30 a.m. ET to discuss its Q1 2021 results and provide a business update. The call can be accessed at 844-277-9450 (domestic) and 336-525-7139 (international) using conference ID 9967338. The company is known for its microbiome therapeutics, particularly the SER-109 program, which has received FDA's Breakthrough Therapy and Orphan Drug designations for treating recurrent C. difficile infection. Its SER-287 and SER-301 programs are also advancing through clinical trials.
Seres Therapeutics, Inc. (Nasdaq: MCRB) will have President and CEO Eric Shaff present at the Jefferies Microbiome-Based Therapeutics Summit on April 22, 2021. The presentation will be pre-recorded and accessible on Seres' website at 8:00 a.m. ET on the same day, remaining available for 21 days. Seres is known for its groundbreaking work in microbiome therapies, including the SER-109 program, which targets recurrent C. difficile infections and has received Breakthrough Therapy designation from the FDA. The company is also advancing several other therapeutic candidates for gastrointestinal diseases.
Seres Therapeutics, (Nasdaq: MCRB), announced its participation in the 31st Annual Oppenheimer Healthcare Conference on March 16 at 9:20 a.m. ET. The company will provide a corporate overview during this event.
A live audio webcast will be accessible on Seres' website, with a replay available one hour post-event for 21 days.
Seres is recognized for its innovative microbiome therapeutics, including the SER-109 program, which has received Breakthrough Therapy designation from the FDA for treating recurrent C. difficile infection.
Seres Therapeutics (Nasdaq: MCRB) announced the voluntary discontinuation of patient enrollment in the MCGRAW study, focusing on SER-401 and nivolumab for metastatic melanoma. This decision follows challenges in enrollment amidst the COVID-19 pandemic. Although the preliminary results from 10 subjects indicated that SER-401 was safe and well-tolerated, the company will deprioritize its development. Seres aims to leverage insights from this study to advance future oncology programs and continues its research in microbiome therapeutics.
Seres Therapeutics (MCRB) reported its Q4 and full year 2020 results, confirming progress in its microbiome therapeutics portfolio. Key highlights include the advancement of SER-109 towards a Biologics License Application (BLA) and achieving target enrollment for the SER-287 ECO-RESET Phase 2b study. SER-109 demonstrated an 88% sustained clinical response in a Phase 3 study for recurrent C. difficile infection, with a significant reduction in recurrence rates. The company enters 2021 with a solid financial position and a robust pipeline targeting multiple diseases.
Seres Therapeutics, Inc. (Nasdaq: MCRB) has announced the successful enrollment of 201 patients in the Phase 2b ECO-RESET clinical trial for SER-287, targeting mild-to-moderate ulcerative colitis (UC). This study aims to assess clinical remission and endoscopic improvement after treatment. The FDA has indicated that this trial may support a Biologics License Application (BLA). The company anticipates sharing topline results in mid-2021, highlighting SER-287's potential as a new therapeutic approach amidst a significant unmet need for safer UC treatments.
Seres Therapeutics, Inc. (Nasdaq: MCRB) announced its participation in two upcoming investor conferences. The Cowen 41st Annual Health Care Conference is set for March 2, 2021, featuring a Microbiome panel discussion and 1x1 meetings. The Chardan 3rd Annual Microbiome Medicines Summit will take place on March 8, 2021, where management will present a corporate overview at 2:30 p.m. ET and conduct 1x1 meetings. An audio webcast for the Chardan presentation will be available on Seres’ website. The company is at the forefront of microbiome therapeutics, with notable programs for recurrent C. difficile infection and ulcerative colitis.
Seres Therapeutics, Inc. (Nasdaq: MCRB) will host a conference call on March 2, 2021, at 8:30 a.m. ET to discuss its fourth quarter and full year 2020 results. The company is a leader in microbiome therapeutics, focusing on multifunctional bacterial therapeutics. Notably, Seres’ SER-109 program has shown positive pivotal clinical results and received Breakthrough Therapy and Orphan Drug designations from the FDA. Additionally, SER-287 is under Phase 2b evaluation for ulcerative colitis, while other programs are in various stages of clinical trials.
Seres Therapeutics (Nasdaq: MCRB) announced new findings from its SER-109 Phase 3 ECOSPOR III clinical study related to recurrent C. difficile infection. The study demonstrated rapid engraftment of SER-109-derived bacteria in the gastrointestinal tract, achieving significant metabolic changes that create an unfavorable environment for C. difficile growth. The data revealed an 88.9% sustained clinical response rate at eight weeks post-treatment, with no serious adverse events reported. SER-109 has received FDA Breakthrough Therapy and Orphan Drug designations.
FAQ
What is the current stock price of Seres Therapeutics (MCRB)?
What is the market cap of Seres Therapeutics (MCRB)?
